Drug Patents owned by Indivior Inc

1. List of Perseris Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406160 INDIVIOR INC Sustained release small molecule drug formulation
Jun, 2026

(3 years from now)

US10058554 INDIVIOR INC Sustained release small molecule drug formulation
Sep, 2026

(3 years from now)

US9597402 INDIVIOR INC Sustained release small molecule drug formulation
Sep, 2026

(3 years from now)

US11110093 INDIVIOR INC Sustained release small molecule drug formulation
Nov, 2026

(3 years from now)

US10010612 INDIVIOR INC Sustained delivery formulations of risperidone compounds
Feb, 2028

(5 years from now)

US9180197 INDIVIOR INC Sustained delivery formulations of risperidone compounds
Feb, 2028

(5 years from now)

US9186413 INDIVIOR INC Sustained delivery formulations of risperidone compounds
Feb, 2028

(5 years from now)

US10376590 INDIVIOR INC Sustained delivery formulations of risperidone compound
Feb, 2028

(5 years from now)

US11013809 INDIVIOR INC Sustained delivery formulations of risperidone compound
Feb, 2028

(5 years from now)

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 27 July, 2018

Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

2. List of Sublocade drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10198218 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US9272044 INDIVIOR INC Injectable flowable composition buprenorphine
Jun, 2031

(8 years from now)

US9498432 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US10592168 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US9827241 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US9782402 INDIVIOR INC Injectable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US10558394 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US8975270 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Sep, 2031

(8 years from now)

US8921387 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jan, 2032

(8 years from now)

US11000520 INDIVIOR INC Buprenorphine dosing regimens
Nov, 2035

(12 years from now)

US10646484 INDIVIOR INC Methods to treat opioid use disorder
Jun, 2038

(15 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treatment of moderate to severe opioid use disorder; Treating opioid addiction by administering buprenorphine; Treating opioid addiction by administering buprenorphine once per month; Treating opioid addiction by administering buprenorphine composition with 28 day dose duration; Treating opioid addiction by subcutaneous injection of buprenorphine; In situ formation of solid buprenorphine composition; Treating opioid dependency by administering buprenorphine; Treating opioid addiction by administration of buprenorphine; Treating opioid dependency by subcutaneously administering buprenorphine; Treating opioid addiction by 100 mg or 300 mg dose buprenorphine; Treating opioid dependency by administering buprenorphine once per month; Treating addiction with 100 mg or 300 mg dose of buprenorphine; Treating addiction by once per month administration of buprenorphine; Treating addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine once monthly; Treating opioid dependence by administering buprenorphine; Treating opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

3. List of Suboxone drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9931305 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Feb, 2022

(11 months ago)

US9855221 INDIVIOR INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(11 months ago)

US10285910 INDIVIOR INC Sublingual and buccal film compositions
Oct, 2022

(3 months ago)

US8017150 INDIVIOR INC Polyethylene oxide-based films and drug delivery systems made therefrom
Feb, 2023

(13 days from now)

US8603514 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(1 year, 2 months from now)

US9687454 INDIVIOR INC Sublingual and buccal film compositions
Aug, 2029

(6 years from now)

US11135216 INDIVIOR INC Sublingual and buccal film compositions
Aug, 2029

(6 years from now)

US8475832 INDIVIOR INC Sublingual and buccal film compositions
Mar, 2030

(7 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

How can I launch a generic of SUBOXONE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in